How a penguin ‘divorce' can impact a whole colony
This connection gives researchers a handy clue for predicting the future health of the colony and protecting it from harm, as penguin habitats get warmer with climate change.
What we know about little blue penguins
Little blue penguins (Eudyptula minor)—also known as little penguins or fairy penguins—are the world's smallest species of penguin, growing to an average of just 12 inches high.
Phillip Island, southwest of Melbourne, is home to around 30,000 of these tiny birds. 'It has the world's largest colony of little penguins,' says Richard Reina, a biologist at Monash University and coauthor of the new study published in Ecology and Evolution exploring the surprising repercussions of penguin divorce.
After a day foraging at sea, the tiny birds return to their burrows in the hillside. Some of the colony live in special nesting boxes and are microchipped, just like a pet cat or dog, so scientists can easily scan them to collect data on any of the birds in the box.
'You can just put a reader and go 'blip' and it tells you who's at home,' says Wilson, who wasn't involved in the study.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
16 hours ago
- Indianapolis Star
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases MIAMI, FL / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' a preclinical-stage biotechnology company focused on reversing biological aging and degenerative diseases, today announced compelling new preclinical data demonstrating that its lead drug candidate, Telomir-1, significantly reversed neurological, hepatic and kidney symptoms in a clinically relevant animal model of Wilson's disease. Wilson's disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body's ability to eliminate excess copper. As copper builds up-primarily in the liver and brain-it leads to inflammation, tissue damage, and multi-organ dysfunction. Patients may experience liver failure, psychiatric disturbances, tremors, and progressive neurological decline. Current treatments involve lifelong copper chelation or liver transplantation, highlighting the urgent need for safer, disease-modifying therapies. These new results build on earlier in vitro studies that confirmed Telomir-1's high binding affinity for copper and its ability to exchange and regulate key ions. The current in vivo findings now confirm that Telomir-1's copper-regulating properties translate into meaningful behavioral, physiological and histological improvements in a genetic animal model of Wilson's disease. In the ATP7B C271X -/- zebrafish model, which mimics human Wilson's disease Telomir-1 demonstrated dose-dependent and statistically significant reversal of major disease features: Key Findings from the Study: Up to a 4- to 5-fold reduction in episodic tremor events Normalization of swim distance, swim velocity, and exploratory behavior Reversal of ataxia-like motor behaviors (e.g., abnormal body bends and turn angles) Approximately 50% reduction in copper accumulation in dry liver tissue Marked improvement in liver and kidney histopathology, with liver and kidney scores reduced to near-normal levels Normalization of ALT, AST, and bilirubin-three critical liver biomarkers. ALT and AST are enzymes elevated during liver injury, while bilirubin builds up when detoxification is impaired. Telomir-1 restored these to wild-type levels, indicating protection of liver function and copper-induced damage Improved survival under high copper exposure conditions 'We've now seen Telomir-1 generate breakthrough results across some of the most challenging age-related and genetic diseases-including AMD, Wilson's disease, cancer, progeroid and Werner syndromes, and early findings suggesting reversal of key factors in type 2 diabetes,' said Erez Aminov, Chairman and CEO of Telomir. 'In our AMD model, Telomir-1 restored vision and regenerated retinal structure using FDA-recognized surrogate endpoints. In Werner syndrome, it reset the epigenetic clock and reversed hallmarks of accelerated aging. And in Wilson's disease, we saw a reversal of neurological, liver and kidney damage. These results point to the broad therapeutic potential of Telomir-1 across diseases driven by cellular degeneration. We believe this positions Telomir-1 as a powerful new platform for longevity, neuroprotection, and regenerative medicine.' 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease,' added Dr. Angel, Chief Scientific Advisor. 'Its ability to reverse behavioral and neurological dysfunction, normalize histological and functional biomarkers, and extend survival underscores its therapeutic promise across both rare and age-related disorders.' Telomir Pharmaceuticals is currently advancing Telomir-1 through IND-enabling studies and expects to file its first IND for a rare disease indication by year-end, with human clinical trials planned for the first half of 2026. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
Associated Press
17 hours ago
- Associated Press
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model
Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival. Building on previous data in Werner syndrome, showing Telomir-1 reset the epigenetic clock, extended telomere length, restored gene expression, reversed muscle loss, and rescued survival-alongside data in Age Related Macular Degeneration (AMD) demonstrating retinal regeneration and restored vision-the drug continues to show broad regenerative potential across rare genetic degenerative diseases MIAMI, FL / ACCESS Newswire / June 11, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' a preclinical-stage biotechnology company focused on reversing biological aging and degenerative diseases, today announced compelling new preclinical data demonstrating that its lead drug candidate, Telomir-1, significantly reversed neurological, hepatic and kidney symptoms in a clinically relevant animal model of Wilson's disease. Wilson's disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body's ability to eliminate excess copper. As copper builds up-primarily in the liver and brain-it leads to inflammation, tissue damage, and multi-organ dysfunction. Patients may experience liver failure, psychiatric disturbances, tremors, and progressive neurological decline. Current treatments involve lifelong copper chelation or liver transplantation, highlighting the urgent need for safer, disease-modifying therapies. These new results build on earlier in vitro studies that confirmed Telomir-1's high binding affinity for copper and its ability to exchange and regulate key ions. The current in vivo findings now confirm that Telomir-1's copper-regulating properties translate into meaningful behavioral, physiological and histological improvements in a genetic animal model of Wilson's disease. In the ATP7B C271X -/- zebrafish model, which mimics human Wilson's disease Telomir-1 demonstrated dose-dependent and statistically significant reversal of major disease features: Key Findings from the Study: 'We've now seen Telomir-1 generate breakthrough results across some of the most challenging age-related and genetic diseases-including AMD, Wilson's disease, cancer, progeroid and Werner syndromes, and early findings suggesting reversal of key factors in type 2 diabetes,' said Erez Aminov, Chairman and CEO of Telomir. 'In our AMD model, Telomir-1 restored vision and regenerated retinal structure using FDA-recognized surrogate endpoints. In Werner syndrome, it reset the epigenetic clock and reversed hallmarks of accelerated aging. And in Wilson's disease, we saw a reversal of neurological, liver and kidney damage. These results point to the broad therapeutic potential of Telomir-1 across diseases driven by cellular degeneration. We believe this positions Telomir-1 as a powerful new platform for longevity, neuroprotection, and regenerative medicine.' 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease,' added Dr. Angel, Chief Scientific Advisor. 'Its ability to reverse behavioral and neurological dysfunction, normalize histological and functional biomarkers, and extend survival underscores its therapeutic promise across both rare and age-related disorders.' Telomir Pharmaceuticals is currently advancing Telomir-1 through IND-enabling studies and expects to file its first IND for a rare disease indication by year-end, with human clinical trials planned for the first half of 2026. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya [email protected] (786) 396-6723 SOURCE: Telomir Pharmaceuticals, Inc press release
New York Post
6 days ago
- New York Post
Exercising within 4 hours of bedtime is messing with your sleep
Sweat dreams? While trying to get ripped is an admirable goal, new research reveals that doing it at night might just be muscling into your REM cycle. High-intensity workouts four hours or less before bed were linked to poorer sleep quality, later bedtimes and a higher resting heart rate. 3 While you may know that working out right before bed isn't good for you, this is the first and most extensive study to understand why. Pormezz – They were also associated with lower heart rate variability, meaning less variation in the time between heartbeats, which is generally a sign of stress or poor recovery. All of the markers indicate strenuous exercise that close to lights out puts the body into a heightened state of alertness, hindering the transition to restful sleep. Strenuous exercise is defined as activities that require a lot of physical effort — typically elevating the heart rate to 70% to 85% of maximum capacity — such as biking uphill, engaging in HIIT or playing sports. While experts have generally agreed that working out right before bed isn't good for you, this is the first and most extensive study to illuminate why. 3 This graphic from the study shows actual exercise timing and strain associations with sleep and nocturnal autonomic activity. Nature Communications (2025) 'Intense exercise in the evening can keep the body in a heightened state of alertness, which is why public health guidelines have previously advised against working out too close to bedtime,' lead author Dr. Josh Leota, a research fellow in the School of Psychological Sciences at Monash University in Melbourne, Australia, said in a statement. 'However, findings from controlled laboratory studies are less conclusive, with many suggesting that evening exercise doesn't necessarily disrupt sleep.' These studies relied on small sample sizes and laboratory settings, Leota said, and rarely involved exercise that made substantial cardiometabolic demands on the body. For his research, Leota and his team analyzed data from 14,689 people over the course of one year, which translated to a whopping 4 million nights of information. Participants wore a health-tracking wristband called WHOOP to monitor their sleep, exercise and heart health. The findings were adjusted for factors such as gender, age and general fitness level, lending further credibility to the study's conclusions. 3 The study found that doing high-intensity workouts four hours or less before bed led to poorer sleep quality, later bedtimes and a higher resting heart rate. oneinchpunch – The results were published recently in the journal Nature Communications. Studies indicate that exercising in general is good for sleep, with some researchers reporting that short, light workouts before bed can help you sleep longer, lower blood sugar levels and potentially live longer. So, if you do find yourself wanting to work out a couple of hours before bed, Leota suggests choosing 'brief low-intensity exercises, such as a light jog or swim, to minimize sleep disruption and allow the body to wind down.' Or, for added gut health benefits — just take a fart walk.
